GET DAILY SIGNALSInsight Molecular Diagnostics (IMDX) Q3 2026 Earnings: Key Focus Areas Ahead of the Report
Key Takeaways
- Insight Molecular Diagnostics (IMDX) is scheduled to report third quarter 2026 results after the market close on Monday, November 16, 2026.
- Consensus estimates point to a loss of roughly $0.23 to $0.24 per share on revenue near $249,000, reflecting the company's early commercialization stage.
- IMDX remains essentially pre-revenue as it awaits U.S. Food and Drug Administration (FDA) authorization for its flagship GraftAssureDx transplant test.
- Investors will focus on the FDA review timeline, cash position, and quarterly cash burn rather than headline revenue.
- In the prior quarter, IMDX posted revenue of $239,000 and a net loss of $11.3 million, with a non-GAAP net loss of $0.23 per share.
Why This Earnings Report Matters
For Insight Molecular Diagnostics, quarterly earnings are less about revenue and more about regulatory milestones. The company is betting its future on GraftAssure, a family of transplant-rejection tests that measure donor-derived cell-free DNA (dd-cfDNA), a blood-based biomarker used to assess organ rejection. The pivotal catalyst is FDA marketing authorization for GraftAssureDx, its in vitro diagnostic (IVD) kit. Management has said it does not expect material kit revenue until that authorization arrives, making the third quarter report a key checkpoint on cash runway, research and development (R&D) spending, and go-to-market readiness ahead of a potential 2026 commercial launch.
Earnings Estimates and Historical Context
Analysts expect IMDX to remain loss-making. Consensus estimates call for a net loss of approximately $0.23 to $0.24 per share, with revenue projected near $249,000, largely from laboratory services. By comparison, the company reported a non-GAAP net loss of $0.23 per share on $239,000 of revenue in the second quarter of 2026, and a loss of $0.34 per share on about $260,000 of revenue in the same quarter a year earlier.
Historical price reactions around IMDX reports have been volatile. The stock fell roughly 7% the day after the August 2026 report, rose about 26% following the May 2026 release, and declined about 13% after the March 2026 update. Given the company's pre-revenue status, investors will likely weigh management's commentary on the FDA review, cash burn guidance, and any early signs of commercial traction in the U.S. and Europe more heavily than the raw financial figures. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Sentiment heading into the third quarter report is cautious but watchful. IMDX shares have experienced significant volatility over the past year, and the stock carries a beta well above the market average, meaning it tends to move more sharply than the broader market. With the company still pre-revenue in its core kitted-test business, the market is primarily pricing the probability of FDA authorization for GraftAssureDx. Key risks include potential regulatory delays, continued cash burn, dilution from past and possible future capital raises, and slower-than-expected adoption even after approval. The stock's reaction will likely hinge less on the loss-per-share figure and more on any forward-looking commentary about the FDA process.
Forward Outlook and Key Factors to Monitor
Following the report, the most important item to watch is the status of the FDA submission for GraftAssureDx, which targets kidney transplant monitoring first. Management has indicated it expects FDA marketing authorization later in 2026, and any update on that timeline will likely be the single biggest driver of investor sentiment.
Cash runway is the second major factor. IMDX ended the first quarter of 2026 with about $29.4 million in cash, cash equivalents, and restricted cash, supported by a $26 million registered direct offering. The company has guided for elevated cash burn early in the year, with quarterly burn expected to decline as heavy FDA-submission-related R&D spending rolls off. Investors should monitor whether the company reaffirms or adjusts that trajectory.
Finally, watch for early commercialization signals, including research-use-only (RUO) GraftAssureIQ kit sales outside the U.S. and any indications of initial U.S. customer interest ahead of potential authorization. Long term, the company is targeting a gross margin of 70% or higher, though it does not expect to reach that level in the first six to twelve months after commercialization.
Using AI Tools in My Research
When analyzing names like IMDX, I frequently rely on Tickeron’s AI Screener to filter opportunities across the diagnostics sector. It allows me to quickly compare technical patterns, fundamentals, and AI-driven signals, helping surface relevant peers or breakout candidates without spending hours on manual screening. This approach has become a regular part of my workflow for staying on top of pre-commercial companies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IMDX in -10.22% downward trend, falling for three consecutive days on November 05, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where IMDX declined for three days, in 289 of 315 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMDX as a result. In 81 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for IMDX turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
The Aroon Indicator for IMDX entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMDX advanced for three days, in 165 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
IMDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.826) is normal, around the industry mean (67.298). P/E Ratio (-1.638) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. IMDX's P/S Ratio (71.942) is very high in comparison to the industry average of (9.775).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. IMDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of ovel, non-invasive, liquid biopsy diagnostics for the early detection of cancer
Industry MedicalSpecialties
Advertisement